Identification of Potential Leukocyte Biomarkers Related to Drug Recovery of CFTR: Clinical Applications in Cystic Fibrosis
Authors:
- Marco PedrazziMarco Pedrazzi
- Silvia VercelloneSVSilvia Vercellone
- Elettra BarberisEBElettra Barberis
- Michela CapraroMCMichela Capraro
- Roberta De TullioRTRoberta De Tullio
- Federico CrestaFCFederico Cresta
- Rosaria CasciaroRCRosaria Casciaro
- Carlo CastellaniCCCarlo Castellani
- Mauro PatroneMauro Patrone
- Emilio MarengoEMEmilio Marengo
- Paola LeccaPLPaola Lecca
- Paola MelottiPMPaola Melotti
Open Access
- 10 April 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (8) , 3928
Abstract
The aim of this study was the identification of specific proteomic profiles, related to a restored cystic fibrosis transmembrane conductance regulator (CFTR) activity in cystic fibrosis (CF) leukocytes before and after ex vivo treatment with the potentiator VX770. We used leukocytes, isolated from CF patients carrying residual function mutations and eligible for Ivacaftor therapy, and performed CFTR activity together with proteomic analyses through micro-LC–MS. Bioinformatic analyses of the results obtained revealed the downregulation of proteins belonging to the leukocyte transendothelial migration and regulation of actin cytoskeleton pathways when CFTR activity was rescued by VX770 treatment. In particular, we focused our attention on matrix metalloproteinase 9 (MMP9), because the high expression of this protease potentially contributes to parenchyma lung destruction and dysfunction in CF. Thus, the downregulation of MMP9 could represent one of the possible positive effects of VX770 in decreasing the disease progression, and a potential biomarker for the prediction of the efficacy of therapies targeting the defect of Cl− transport in CF.Keywords
Funding Information
- Fondazione per la Ricerca sulla Fibrosi Cistica (FFC #29/2015 and #12/2019.)
This publication has 43 references indexed in Scilit:
- Calpain Inhibition Promotes the Rescue of F508del-CFTR in PBMC from Cystic Fibrosis PatientsPLOS ONE, 2013
- Mechanism-based corrector combination restores ΔF508-CFTR folding and functionNature Chemical Biology, 2013
- Deletion of CFTR Translation Start Site Reveals Functional Isoforms of the Protein in CF PatientsCellular Physiology and Biochemistry, 2009
- Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patientsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- Induced sputum matrix metalloproteinase‐9 correlates with lung function and airway inflammation in children with cystic fibrosisPediatric Pulmonology, 2005
- CFTR and Chaperones: Processing and DegradationJournal of Molecular Neuroscience, 2004
- Five Percent of Normal Cystic Fibrosis Transmembrane Conductance Regulator mRNA Ameliorates the Severity of Pulmonary Disease in Cystic FibrosisAmerican Journal of Respiratory Cell and Molecular Biology, 2002
- Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alphaThorax, 2002
- Mechanism and Cellular Applications of a Green Fluorescent Protein-based Halide SensorJournal of Biological Chemistry, 2000
- Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNAScience, 1989